Introduction {#Sec1}
============

Infections with parasitic gastrointestinal nematodes (GIN) are common among grazing cattle worldwide, and may cause serious economic losses due to decreased growth of their hosts (Sutherland and Leathwick [@CR41]). In Sweden, the most important GIN species include *Cooperia oncophora* (Fig. [1](#Fig1){ref-type="fig"}) and the more pathogenic *Ostertagia ostertagi,* which usually are present as mixed infections in grazing cattle (Höglund [@CR15]). Regular strategic treatment with anthelmintic drugs, as topical or injectable formulations, remains the principal means of control of helminth infections (Prichard et al. [@CR38]). Lately, reports have shown that a worldwide spread of anthelmintic resistance (AR) has occurred, probably due to an extensive usage of anthelmintics in the cattle livestock industry (Demeler et al. [@CR8]; Gasbarre et al. [@CR13]; Sutherland and Leathwick [@CR41]). However, the underlying mechanisms of AR development in cattle nematodes remain essentially unknown. It is understood that drug resistance can arise in four different ways: a change in the molecular target causing failure at the binding site, changes in drug metabolism preventing activation or removing the drug, changes in drug distribution in the target organism, or amplification of target genes that overcome drug action (Wolstenholme et al. [@CR46]).Fig. 1*C. oncophora*, bursa and spicules of adult male

Ivermectin (IVM) is one of several anthelmintics in the group of macrocyclic lactones (ML), which has been extensively used in the control of parasitic nematodes of livestock since they were introduced in the early 1980s (Omura [@CR34]). MLs act through irreversible binding to γ-aminobutyric acid- and glutamate-gated chloride (GluCl) channels, causing hyperpolarisation and thus paralysis of pharyngeal and somatic muscle cells, leading to starvation and expulsion of worms from the GI tract (Blackhall et al. [@CR4], [@CR5]; Martin et al. [@CR30]; Rana and Misra-Bhattacharya [@CR39]). It has been shown for the model organism *Caenorhabitidis elegans* (Cully et al. [@CR6]; Dent et al. [@CR10]; Lynagh and Lynch [@CR28]; McCavera et al. [@CR31]) as well as for *C. oncophora* (Njue et al. [@CR33]) that IVM resistance can be associated with mutations in *GluCl*, resulting in receptor conformation changes and lowered sensitivity to IVM. However, the mechanisms behind IVM resistance are complex, and there are many studies that suggest the involvement of P-glycoproteins (PGP). PGPs are part of a larger superfamily of transmembrane efflux transporters that have been implicated as a primary cause of anthelmintic resistance both in *C. elegans* and in the abomasal sheep nematode *Haemonchus contortus* (Blackhall et al. [@CR3]; James and Davey [@CR19]; Kerboeuf et al. [@CR22]). PGPs, for which IVM is a well-known substrate (Kerboeuf and Guegnard [@CR21]; Lespine et al. [@CR25]), are members of the ATP binding cassette (ABC) superfamily of genes coding for molecules involved in active transport of endo- and exogenous hydrophobic molecules (Jones and George [@CR20]). Dupuy et al. ([@CR12]) showed that PGPs are involved in the pharmacokinetics of IVM, and recently Kerboeuf and Guegnard ([@CR21]) found evidence that MLs activate transport activity in nematode PGP, and suggest that several substituents in the ML structure are involved in modulating the stimulatory effect. Altogether, 14 isoforms of PGP plus 1 pseudogene have been annotated in the *C. elegans* genome database (WormBase, version: WS234).

The majority of ML-resistance studies to date have investigated target site mutations. Some attention has been paid to the role of changes in gene expression, and upregulation in helminth PGP gene expression has been suggested to enhance the parasite's ability to survive exposure to IVM. The potential effect of this may be an increased membrane transport and thus faster drug elimination. Recently, PGP expression from several variants of PGP in *Teladorsagia circumcincta* from sheep was investigated in IVM-resistant isolates (Dicker et al. [@CR11]). One of the PGP, *Tci-Pgp-9*, showed increased expression at the mRNA level and nucleotide sequences also showed high levels of polymorphism, which could play an important role in helminth survival of IVM exposure. Pachnicke ([@CR36]) performed similar studies in a benzimidazole (BZ)-selected *O. ostertagi* population and found evidence of increased PGP-related signals in eggshells from BZ-selected *O. ostertagi*, but no signs of increased PGP gene expression in adult worms.

In the summers of 2006 and 2007, the efficacy of ML (Ivomec inj.®) was investigated in five cattle herds in the Uppsala region of central Sweden (Demeler et al. [@CR8]). The evaluation was made among first season grazing (FSG) cattle some weeks after turnout, and was conducted using the faecal egg count reduction test (FECRT). It showed unsatisfactory efficacy results, with only one farm reaching acceptable reductions of egg output in 2006. In 2007, the reduction was insufficient on all farms where animals were treated with IVM. Isolates from two of these farms were collected, and a pen trial was carried out to investigate the effect of injectable IVM under controlled conditions (unpublished data, Areskog et al.). The objectives of the current study were to further characterise the recovered worms in vitro and to compare PGP expression in adult worms before and after treatment.

Materials and methods {#Sec2}
=====================

Parasites {#Sec3}
---------

During 2009, an IVM selection trial was carried out where three groups, each of 11 FSG, were experimentally inoculated with mixtures of 40,000 infective third stage (L3) larvae of *C. oncophora* and *O. ostertagi*. The study in its entirety will be presented in a separate publication, but in brief, control group A received an equal mixture of L3 from each of two laboratory isolates from Tierärztliche Hochschule, Hannover, originating from the Central Veterinary Laboratory at Weybridge, UK. Both isolates had no history of being refractory to treatment with any anthelmintics in vitro (Demeler et al. [@CR9]). Calves in groups B and C were inoculated with mixed L3 isolated from the Swedish farms showing poor reductions to IVM according to FECRT: 84 % \[95 % confidence interval (CI), 67--95\] and 85 % (62--99) reductions, respectively, at day 7 (Demeler et al. [@CR8]). All animals were injected with IVM at the standard dose rate of 0.2 mg IVM per kg 35 days post-infection (d.p.i). Four days before IVM treatment (31 d.p.i), one animal per group (A, B and C) was euthanized intravenously with pentobarbital (ex tempore 300 mg/ml, 60 ml/calf). Another two animals per group were euthanized 10 days post-IVM treatment (45 d.p.i). Individual faecal samples were also collected rectally at the day of slaughter. A modified McMaster method (Anonymous [@CR1]) was used to determine the number of parasite eggs in 3 g of faeces, giving a diagnostic sensitivity of 50 eggs per gram faeces (EPG). Animals were treated, and the trial was performed according to formal institutional ethical approval (C276/8).

At slaughter, worms were basically recovered according to Larsson et al. ([@CR24]). Briefly, the abomasum and ∼7 m of the proximal small intestine (duodenum, jejunum) were separated, and their content emptied into individual vessels. The mucosal surfaces were washed with tap water, and from each animal, five male and five female adult worms were immediately recovered and stored at --80 °C in individual Eppendorf tubes until analysis. In addition, 20-ml aliquot subsamples were collected and stored at --20 °C for worm counts and additional analysis. Also, the abomasal mucosa was scraped off and digested in a pepside solution for *O. ostertagi* recovery.

Isolation of RNA {#Sec4}
----------------

Total worm RNA was isolated, using Macherey-Nagel NucleoSpin RNA II columns with DNAse I, individually from five single male and five female *C. oncophora* each pre- and post (10 days) IVM treatment, from three different isolates, giving in total 60 worms. The three isolates represented the propagated susceptible control group plus two isolates showing signs of phenotypic clinical ML resistance according to previous FECRT results. Washing buffers and rDNAse buffer were used to remove contaminating DNA, and integrity of the RNA was checked visually following electrophoresis. Eluates were kept frozen at --80 °C for long-term storage. RNA quantification was performed according to the RiboGreen protocol (Invitrogen) using aVictor2 1420 Multilabel counter (Wallac).

Primer design {#Sec5}
-------------

A conserved 202-bp PGP sequence from *C. oncophora* (Pachnicke [@CR36]) was identified by ClustalW2 as having 83 % similarity to the *PGP-9* of *C. elegans*. Primers specific to this conserved PGP sequence were then designed in Primer3, generating a 153-bp PCR product. Sequencing of the PCR product was performed, followed by a BLAST search in Wormbase (genome view), which was identified as WBGene00004003.

RT-qPCR {#Sec6}
-------

One-tube RT-PCR QuantiTect with SYBR Green (Qiagen) was used to measure PGP gene expression by RT-qPCR using known concentrations of PGP-PCR product as standards and non-template controls as blanks. The primer sequences used were *C. elegans Pgp-9* Forward 5′ CGA ACG AGG TGT GCA ACT AA 3′ and *C. elegans Pgp-9* Reverse 5′ GCC TTC TCC AAA GCT TCT TGT 3′. The 25-μl RT-PCR reactions contained 12.5 μl 2× QIAGEN Quanti Tect SYBR Green master mix, 0.5 μl Forward primer (10 μM), 0.5 μl reverse primer (10 μM), 0.25 μl Q-RT, 1.25 μl of RNAse-free H~2~O and 10 μl RNA sample adjusted to contain 2 ng total RNA from each single worm. Thus, PGP expression was normalised to the amount of total RNA in the PCR reaction as previously described by Tyden et al. ([@CR43]). All samples were run in technical duplicates. To determine the level of expression of PGPs before and after treatment, a standard curve was applied using five concentrations of the purified and sequenced 153 bp PGP-PCR product diluted from 7,000 to 0.7 ag μl^−1^ in tenfold titrations. The PGP-PCR product was quantified by applying PicoGreen reagent (Invitrogen) according to the instructions of the manufacturer and a Victor2 1420 Multilabel counter (Wallac). To minimise the risk of amplifying genomic DNA, the samples were DNAse treated during RNA isolation, as previously described.

RNA samples were run in a Rotor-Gene 3000 (Corbett) and the data analysed using Rotor-Gene 6.1.90 software (Corbett). The RT-qPCR conditions were as follows: RT step, 50 °C for 30 min; Taq-polymerase activation step, 95 °C for 15 min followed by 45 cycles of 94 °C for 60 s, 55 °C for 60 s and 68 °C for 45 s and a final extension step at 68 °C for 7 min. Melting curve analysis was performed for each sample in direct connection to the PCR, to verify that no secondary products were generated. To quantify the relative changes in expression of putative *Con-pgp-9* before and after IVM treatment, the 2^−Δ*C*T^ method of Livak and Schmittgen ([@CR26]) was used. In addition, in order to measure absolute *Con-pgp-9* expression, absolute gene concentrations were also calculated from the standard curve.

Amplified fragment length polymorphism {#Sec7}
--------------------------------------

### DNA extraction {#Sec8}

DNA was prepared from individual worms using a QIAamp DNA Micro Kit (Qiagen) according to the manufacturer's recommendation. Samples were eluted in 30 μl buffer AE. Treatment with RNaseA was performed post-DNA isolation by adding 60 μg of RNaseA to 30 μl of sample and incubating for 5 min at room temperature to obtain RNA-free samples. The purified DNA was stored at −20 °C until use.

### AFLP procedure {#Sec9}

In total, 108 adult *C. oncophora* of both sexes were used for AFLP analysis, but unlike the worms used for gene expression studies, these were recovered from aliquots frozen at −18 °C (Table [1](#Tab1){ref-type="table"}). The AFLP procedure was performed basically as described by Applied Biosystems (ABI) in their Plant Mapping Protocol and in accordance with Höglund et al. ([@CR16]). All reagents were supplied in the AFLP® Plant Mapping Kit (ABI), except for the restriction enzymes and the T4 DNA ligase, which were purchased from New England BioLabs. For all worms, the maximum allowed volume, 5.5 μl, of extracted DNA was used. The DNA from each individual worm was digested with 1 unit of MseI and 5 units of EcoRI, and MseI adaptor and EcoRI adaptor were ligated in the same reaction as the digestion. After the restriction--ligation reaction, the mixture was diluted to a total volume of 50 μl with TE~0.1~ (20 mM Tris--HCl, 0.1 mM EDTA, pH 8.0). From the restriction--ligation reaction, 4 μl of the diluted DNA was mixed with 1 μl of the ABI pre-selective primer pairs (5 μM) and 15 μl of ABI's Core Mix for pre-selective amplification. The amplified products were diluted to a final volume of 200 μl. The FAM dyed EcoRI-ACA + MseI-CTC primer combination was used for selective amplification. From the selective amplification products, 1.0 μl was mixed with 9.6 μl deionised formamide and 0.4 μl GeneScan-500 size standard (ABI). The mixture was denaturated for 3 min at 95 °C, before being loaded onto the ABI Prism 3100 Genetic Analyzer and analysed using GeneMapper analysis software 4.0.Table 1EPG data from day of slaughter and estimated numbers of adult worms recovered in 20 ml subsamples at necropsy, from calves before and 10 days after injection with ivermectin (Ivomec®, Merial) at a dose rate of 0.2 mg IVM/kgTreatmentCalfOrigin*O. ostertagiC. oncophora*EPGMalesFemalesMalesFemalesBefore IVMA1TiHo2,0703,2306,4705,270750B1Gråmunkehöga5706709,07013,6001,000C1Kolsta9002,9001,9303,070400After IVMA2TiHo003,3305,730150A3TiHo00130400\<50B2Gråmunkehöga006,0006,20050B3Gråmunkehöga1000200200\<50C2Kolsta006001,600\<50C3Kolsta001,0002,000\<50Calves were previously each inoculated with a mixture of 40,000 L3 of *C. oncophora* and *O. ostertagi*, representing isolates with different deworming history. Calves A1, A2 and A3 were inoculated with equal mixtures of laboratory-maintained *C. oncophora* and *O. ostertagi* from TiHo, whereas B1, B2, B3, C1, C2 and C3 were inoculated with cattle nematodes from two different farms in Uppland, Sweden, showing phenotypic clinical IVM resistance in previous field trials. Ten worms from each calf were immediately recovered and stored separately at −80 °C for RT-qPCR, and excessive worms were stored at −20 °C for AFLP analysis

Statistical analysis {#Sec10}
--------------------

Data were summarised in Microsoft Excel (2007), whereas statistical analyses and graphs were done in Minitab (version 15). Gene expression was analysed by sex using both log transformed- and original concentrations, and where we compared duplicate mean concentrations, before and after treatment with two sample *t* tests. In addition, a three-factor ANOVA (GLM) comparing treatment × isolate × sex, with isolate as a random factor, was performed. The significance level was set to *p* \< 0.05.

The estimates of allele frequencies for each isolate used the Bayesian method with informative priors of Zhivotovsky ([@CR48]). The calculation of genetic diversity (*H*~j~) and population structure (*F*~st~) from these estimates followed the procedures of Lynch and Milligan ([@CR29]), with 2,000 randomizations used for the statistical tests. These statistics were all computed using the AFLPSurvey program of Vekemans ([@CR44]).

Results {#Sec11}
=======

Parasites {#Sec12}
---------

Faecal egg counts revealed patent infections in all animals at slaughter, both pre-treatment and 10 days post-IVM treatment (Table [1](#Tab1){ref-type="table"}). At necropsy, mainly low to moderate numbers of *C. oncophora* remained in the small intestines of all IVM-treated animals (Table [1](#Tab1){ref-type="table"}). The worm burden showed large variation within groups and no significant difference (*p* = 0.510) between groups.

RT-qPCR {#Sec13}
-------

The expression of the putative *Con-pgp-9* before treatment was compared to the results after treatment for each isolate, and males and females separately. Reaction efficiency of the qPCR was 1.08 in females and 0.97 in males. All samples had concentrations within the range of the standard curve, and female worms had an approximately five times higher gene expression compared to male worms before treatment (Table [2](#Tab2){ref-type="table"}).Table 2RT-qPCR results showing concentrations of putative *Con-pgp-9* RNA expression (ag/2 ng total RNA) in isolates before and 10 days after selection with injectable ivermectin at a dose rate of 0.2 mg ivermectin/kg body weightFemalesMalesIsolateMedianMeanSDSign. *p* (95 % CI)MedianMeanSDSign. *p* (95 % CI)AllBefore153172124202725After831962500.7474446320.091ABefore1221213842397After4584203430.1254444350.764BBefore15515437132941After83108650.2134841210.571CBefore30124220317179After5560330.1194054430.137Group A was infected with a propagated IVM-susceptible laboratory isolate, and groups B and C were infected with two different field isolates showing phenotypic clinical IVM resistance in field trials

The RT-qPCR results demonstrated that mean putative *Con-pgp-9* expression in ML-treated male worms was 70 % higher than in the untreated worms, with mean concentrations of 27 (±25) ag μl^−1^before treatment and 46.2 (±32) ag μl^−1^ after treatment, respectively (Table [2](#Tab2){ref-type="table"}). Although mean concentrations and boxplots (Fig. [2](#Fig2){ref-type="fig"}) suggested a tendency for increased *Con-pgp-9* gene expression after treatment, the statistical analysis showed no significant difference (*p* = 0.091).Fig. 2Boxplot of quantitative putative *Con-pgp-9* expression, males, all groups, 15 worms before- and 15 worms after selection. Isolate A was propagated IVM susceptible, whereas B and C were two different field isolates showing phenotypic clinical IVM resistance in field trials

In females, mean concentrations of PGP were 172 (±SD of 124) ag μl^−1^ before treatment and 196 (±250) ag μl^−1^ after treatment (Table [2](#Tab2){ref-type="table"}). However, as with the male worms, no significant difference (*p* = 0.747) in concentrations was seen in comparisons between any group pre- and post-selection (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Boxplot of quantitative putative *Con-pgp-9* expression, females, all groups, 15 worms before- and 15 worms after selection. Isolate A was propagated IVM susceptible, whereas B and C were two different field isolates showing phenotypic clinical IVM resistance in field trials

The two-sample *t* test showed large variance within female worm groups. Comparing sex and treatment gave no significance (*p* = 0.091 and *p* = 0.747, respectively), but the three-factor ANOVA, with isolate as a random factor, showed that the isolates behaved very differently (*p* = 0.006). Log transformed concentrations gave similar results (data not shown).

AFLP {#Sec14}
----

AFLP showed no bottleneck effect within the population after treatment, with mean gene diversity (*H*~j~) values of 0.158 before treatment and 0.153 after treatment (Table [3](#Tab3){ref-type="table"}). Inbreeding coefficient (*F*~ST~) in subpopulations compared to the total population was 0.0112.Table 3AFLP results derived from adult worms showing high gene diversity (*H* ~j~) values ranging between 0.139 and 0.169 in isolates before and 10 days after selection with injectable IVM at a dose rate of 0.2 mg IVM/kgIsolateSex*NH* ~j\ before~*nH* ~j\ after~AM70.1685390.14800F80.15319130.16727BM90.15288100.13926F80.1673390.15734CM80.1470490.15325F50.15879130.1522545**0.15796**63**0.152895**Isolate A was propagated IVM susceptible, whereas B and C were two different field isolates showing phenotypic clinical IVM resistance in field trials. Average within-population genetic diversity, measured as expected heterozygosity or gene diversity; before and after is equal (*H* ~j~ = 0.158 before and 0.153 after) and thus negatively related to population bottleneck effect. *F* ~st~ (inbreeding coefficient) due to non-random mating in subpopulations relative to the total population, where 0 = no differentiation and 1 = complete differentiation, is low (0.0112), suggesting very little differentiation; *F* ~st~ = 0.0112

Discussion {#Sec15}
==========

In closely related GI nematodes of sheep, ML resistance has been suggested to be linked to an overexpression of PGPs (Blackhall et al. [@CR3]; Dicker et al. [@CR11]; Williamson et al. [@CR45]). Our hypothesis in this study was that changes in expression of efflux pumps such as PGPs would be affected in *C. oncophora*, which survive ML treatment, and/or in isolates with different deworming histories. Increased expression of this molecule has previously been suggested to play a role in drug resistance towards malaria, HIV and cancer, and in nematodes, it has been connected to ML resistance (Gupta and Gollapudi [@CR14]; James and Davey [@CR19]; Loo and Clarke [@CR27]; Xu et al. [@CR47]). Unlike most studies previously performed, we made an attempt to measure PGP expression levels in individual adult worms of *C. oncophora*, employing replicates reflecting the biological diversity in PGP expression. Our results demonstrate a wide distribution and no statistically significant differences in *Con-pgp-9* expression pre- and post-IVM treatment.

It has previously been reported that several anthelmintics may cause an augmented PGP expression in various nematodes (Pachnicke [@CR36]; Williamson et al. [@CR45]; Dicker et al. [@CR11]). The reasons for the discrepancy between our results and the ones previously reported are speculative. However, one possible explanation may include analyses of pooled samples missing the biological diversity by performing statistics on technical repeats. Also, use of BZ instead of IVM may influence the PGP expression in a different manner, or worm-specific sensitivity in the upregulation of PGP. Thus, it cannot be excluded that *C. oncophora* responds differently to anthelmintic treatment than *O. ostertagi* (Pachnicke [@CR36]), *H. contortus* (Williamson et al. [@CR45]) and *T. circumcincta* (Dicker et al. [@CR11]). It is also often hypothesized that anthelmintic exposure itself induces expression of ABC transporter genes in nematodes, experimental evidence is still scarce (Ardelli and Prichard [@CR2]; James and Davey [@CR19]).

The results showed no significant differences before and after ML treatment between the three *C. oncophora* isolates (A, B and C), each with a different deworming history, possibly due to small sample sizes. However, there was a tendency towards increasing putative *Con-pgp-9* expression in male worms (*p* = 0.091). Female worms seemed to give higher and more variable results (*p* = 0.747) than male worms, possibly due to the presence of varying amounts of eggs also expressing PGP (Kerboeuf et al. [@CR23]; Riou et al. [@CR40]). The non-significant statistical results in the comparisons between sex and treatment might be a result of different expression patterns in the investigated isolates. For instance, females in groups B and C actually reduced their mean *Con-pgp-9* expression after ML treatment. This was in contrast to all the other groups and, hypothetically, it could be explained by a decrease in intrauterine egg production, and thus lower mRNA levels for expression of PGP in egg shells during IVM influences. It has previously been shown that the nematode uterine muscle is one of the most susceptible target organs for MLs (Prichard [@CR37]), which could mean that the drug may temporarily suppress egg laying even though adult worms survive treatment. This would make fecund female worms unsuitable for investigation as it causes difficulties in distinguishing between worm- and egg PGP expression levels. However, the same situation did not seem to occur among females in the lab isolate, group A. The differences between groups, rather than differences before or after treatment, were also confirmed by statistical analysis. Clearly, a larger sample size is required to better ensure the effect of ML on individual worms, but the sampling method is both labor-intensive, expensive and demands euthanizing of animals to collect large number of adults surviving deworming. Sometimes we also had problems to isolate enough RNA from the worms, especially from the males, and the number of surviving worms was limited.

Our results therefore can neither support nor exclude that *Con-pgp-9* is involved in the increased incidence of resistance to IVM in this cattle nematode, as has recently been reported for *T. circumcincta* in sheep (Dicker et al. [@CR11]). Another factor that may explain the differing results is the time of sampling. Pachnicke ([@CR36]) collected worms 7 days post-treatment, while in other studies, it is unclear when donor animals were sacrificed. In this study, we investigated worms 10 days post-treatment; however, it is not known when would be the best time to measure changes in *Con-Pgp-9* expression after ML treatment. In a most recently published investigation conducted in parallel to this, De Graef et al. ([@CR7]) examined effects of IVM treatment on the transcription of *C. oncophora* PGPs. In agreement with our findings, no significant differences with respect to *Con*-*Pgp-9* expression were recorded between adults of susceptible and IVM-resistant Belgian *C. oncophora* isolates. Neither could any differences be seen between adults from the resistant isolate being ML-exposed or unexposed. However, in the latter adult worms, a 3.1- and 4.7-fold increased expression of *Con-Pgp-11* was encountered in association with IVM and moxidectin, respectively, after in vivo exposure. Further experiments are thus clearly required to verify the results obtained in the present study, but also to elucidate additional resistance mechanisms that may be involved.

When our *C. oncophora* isolates were analysed with AFLP, we found no evidence of genetic bottlenecking in either of the drug-selected worms, and by comparing their genetic makeup pre- and post-treatment. In veterinary parasitology, AFLP has previously been used mainly to compare the genetic structures of various parasitic nematodes of livestock with different geographic backgrounds (Höglund et al. [@CR18], [@CR17]; Nejsum et al. [@CR32]; Troell et al. [@CR42]), but also to compare consecutive stages of increased benzimidazole- and levamisole-resistant isolates during selection (Otsen et al. [@CR35]). Höglund et al. ([@CR17]) concluded that most nematodes of domesticated hosts usually have very little genetic difference between populations, and are characterised by strong gene flow and expanding populations. In accordance with Otsen et al. ([@CR35]), we found no significant changes in the genetic diversity of isolates associated with anthelmintic selection. However, in contrast to the high level of genetic variation in *H. contortus*, our obtained *C. oncophora* inbreeding coefficient, *F*~ST~, was low, suggesting no genetic differentiation. This agrees with the results from Höglund et al. ([@CR17]) and could mean that, if genetic resistance establishes regionally, then a rapid spread of resistance development would be enabled within the equivalent genetic pool.

In conclusion, comparison of putative *Con-pgp-9* expression before and after IVM treatment showed no significant difference between the tested groups, but some tendency towards increasing expression in male as compared to female worms. Additional research is required to elucidate whether AR observed in *C. oncophora* involves increased expression and activity of PGP or whether this is related to some other transmembrane efflux transporter or metabolic enzyme.

The authors would like to thank PARASOL and GLOWORM (EU projects) for the financial support. We also thank Mr. Husam Babokir who contributed with technical assistance, and associate professor David Morrisson for advice in statistical analysis.
